A detailed history of New York State Common Retirement Fund transactions in Arvinas, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 28,542 shares of ARVN stock, worth $301,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,542
Previous 23,913 19.36%
Holding current value
$301,688
Previous $175,000 38.86%
% of portfolio
0.0%
Previous 0.0%

Shares

34 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 03, 2025

BUY
$6.24 - $8.53 $28,884 - $39,485
4,629 Added 19.36%
28,542 $243,000
Q2 2025

Oct 08, 2025

SELL
$6.07 - $9.62 $2,428 - $3,847
-400 Reduced 1.65%
23,913 $175,000
Q2 2025

Aug 13, 2025

SELL
$6.07 - $9.62 $2,428 - $3,847
-400 Reduced 1.65%
23,913 $176,000
Q1 2025

Oct 08, 2025

BUY
$7.02 - $20.5 $27,293 - $79,704
3,888 Added 19.04%
24,313 $170,000
Q1 2025

May 01, 2025

BUY
$7.02 - $20.5 $27,293 - $79,704
3,888 Added 19.04%
24,313 $171,000
Q4 2024

Oct 08, 2025

SELL
$17.83 - $28.04 $37,443 - $58,884
-2,100 Reduced 9.32%
20,425 $391,000
Q4 2024

Jan 31, 2025

SELL
$17.83 - $28.04 $37,443 - $58,884
-2,100 Reduced 9.32%
20,425 $392,000
Q3 2024

Oct 08, 2025

SELL
$23.66 - $32.73 $32,840 - $45,429
-1,388 Reduced 5.8%
22,525 $554,000
Q3 2024

Oct 28, 2024

SELL
$23.66 - $32.73 $92,274 - $127,646
-3,900 Reduced 14.76%
22,525 $555,000
Q2 2024

Oct 08, 2025

BUY
$24.46 - $40.4 $61,443 - $101,484
2,512 Added 10.5%
26,425 $703,000
Q2 2024

Jul 31, 2024

BUY
$24.46 - $40.4 $152,557 - $251,974
6,237 Added 30.89%
26,425 $703,000
Q1 2024

Oct 08, 2025

SELL
$36.38 - $52.31 $135,515 - $194,854
-3,725 Reduced 15.58%
20,188 $833,000
Q1 2024

May 07, 2024

SELL
$36.38 - $52.31 $1,891 - $2,720
-52 Reduced 0.26%
20,188 $833,000
Q4 2023

Oct 08, 2025

SELL
$14.19 - $42.33 $52,119 - $155,478
-3,673 Reduced 15.36%
20,240 $833,000
Q4 2023

Feb 01, 2024

SELL
$14.19 - $42.33 $1,106 - $3,301
-78 Reduced 0.38%
20,240 $833,000
Q3 2023

Oct 08, 2025

SELL
$19.64 - $28.21 $70,605 - $101,414
-3,595 Reduced 15.03%
20,318 $399,000
Q3 2023

Nov 07, 2023

BUY
$19.64 - $28.21 $2,985 - $4,287
152 Added 0.75%
20,318 $399,000
Q2 2023

Oct 08, 2025

SELL
$21.73 - $31.43 $81,422 - $117,768
-3,747 Reduced 15.67%
20,166 $500,000
Q2 2023

Aug 07, 2023

SELL
$21.73 - $31.43 $118,363 - $171,199
-5,447 Reduced 21.27%
20,166 $501,000
Q1 2023

Oct 08, 2025

SELL
$26.15 - $37.26 $280,066 - $399,054
-10,710 Reduced 29.49%
25,613 $699,000
Q1 2023

May 02, 2023

SELL
$26.15 - $37.26 $280,066 - $399,054
-10,710 Reduced 29.49%
25,613 $700,000
Q4 2022

Oct 08, 2025

BUY
$32.47 - $57.24 $402,952 - $710,348
12,410 Added 51.9%
36,323 $1.24 Million
Q4 2022

Jan 30, 2023

SELL
$32.47 - $57.24 $844 - $1,488
-26 Reduced 0.07%
36,323 $1.24 Million
Q3 2022

Nov 08, 2022

BUY
$41.87 - $57.99 $83,530 - $115,690
1,995 Added 5.81%
36,349 $1.62 Million
Q2 2022

Aug 04, 2022

SELL
$36.01 - $74.24 $2,628 - $5,419
-73 Reduced 0.21%
34,354 $1.45 Million
Q1 2022

May 05, 2022

BUY
$60.27 - $81.57 $178,700 - $241,855
2,965 Added 9.42%
34,427 $2.32 Million
Q4 2021

Feb 02, 2022

SELL
$65.85 - $96.21 $6,453 - $9,428
-98 Reduced 0.31%
31,462 $2.58 Million
Q3 2021

Nov 02, 2021

SELL
$73.2 - $107.87 $448,130 - $660,380
-6,122 Reduced 16.25%
31,560 $2.59 Million
Q2 2021

Aug 02, 2021

BUY
$60.45 - $84.26 $391,836 - $546,173
6,482 Added 20.78%
37,682 $2.9 Million
Q4 2020

Feb 08, 2021

BUY
$20.19 - $84.93 $88,836 - $373,692
4,400 Added 16.42%
31,200 $2.65 Million
Q2 2020

Aug 07, 2020

BUY
$29.88 - $56.74 $185,256 - $351,788
6,200 Added 30.1%
26,800 $899,000
Q4 2019

Feb 05, 2020

BUY
$15.39 - $44.38 $40,014 - $115,388
2,600 Added 14.44%
20,600 $846,000
Q2 2019

Aug 09, 2019

BUY
$15.96 - $23.8 $212,268 - $316,540
13,300 Added 282.98%
18,000 $396,000
Q1 2019

May 08, 2019

BUY
$13.55 - $23.79 $63,685 - $111,813
4,700 New
4,700 $69,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $562M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.